GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » EV-to-Revenue

Aspira Womens Health (FRA:CUL) EV-to-Revenue : 3.09 (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Aspira Womens Health EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aspira Womens Health's enterprise value is €25.70 Mil. Aspira Womens Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €8.31 Mil. Therefore, Aspira Womens Health's EV-to-Revenue for today is 3.09.

The historical rank and industry rank for Aspira Womens Health's EV-to-Revenue or its related term are showing as below:

FRA:CUL' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.09   Med: 20.85   Max: 202.15
Current: 3.09

During the past 13 years, the highest EV-to-Revenue of Aspira Womens Health was 202.15. The lowest was 2.09. And the median was 20.85.

FRA:CUL's EV-to-Revenue is ranked better than
51.57% of 223 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.23 vs FRA:CUL: 3.09

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Aspira Womens Health's stock price is €2.02. Aspira Womens Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.84. Therefore, Aspira Womens Health's PS Ratio for today is 2.40.


Aspira Womens Health EV-to-Revenue Historical Data

The historical data trend for Aspira Womens Health's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health EV-to-Revenue Chart

Aspira Womens Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.15 148.47 24.28 3.91 4.77

Aspira Womens Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.85 2.89 5.71 4.77 4.18

Competitive Comparison of Aspira Womens Health's EV-to-Revenue

For the Diagnostics & Research subindustry, Aspira Womens Health's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's EV-to-Revenue falls into.



Aspira Womens Health EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aspira Womens Health's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=25.696/8.31
=3.09

Aspira Womens Health's current Enterprise Value is €25.70 Mil.
Aspira Womens Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aspira Womens Health  (FRA:CUL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aspira Womens Health's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.02/0.84
=2.40

Aspira Womens Health's share price for today is €2.02.
Aspira Womens Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.84.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aspira Womens Health EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (FRA:CUL) Business Description

Traded in Other Exchanges
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines